L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors : Impact on Tumor Recurrence and Potential Role in Tumor Progression
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
Mucinous ovarian carcinoma (MOC) is a rare histotype of primary ovarian carcinoma. Frequent pathogenic molecular alterations include mutations in KRAS , TP53 , and overexpression of human epidermal growth factor receptor 2, but without having prognostic relevance. As L1-CAM (cell adhesion molecule) has previously shown prognostic relevance in other epithelial tumors of the female genital tract, we analyzed whether L1-CAM expression affected MOC prognosis. In addition, we investigated L1-CAM expression in mucinous borderline tumors (MBOTs) with and without adjacent MOC to identify its potential role in the pathogenesis of MOC. We examined a well-characterized collective of 39 MOCs by immunohistochemistry and compared their expression with clinicopathologic data. L1-CAM positivity was defined as any (even single-cell) positivity. Furthermore, we compared the L1-CAM expression in 20 MBOT regions adjacent to a MOC with that of 15 pure MBOTs. L1-CAM expression in MOC was significantly associated with recurrence, independent of tumor stage. Overall, 7/20 positive cases recurred versus 0/19 L1-CAM-negative cases ( P =0.032), showing a significant difference in time to progression. Furthermore, the presence of at least 1 defined molecular alteration (L1-CAM, aberrant p53, or human epidermal growth factor receptor 2) was found more frequently in the MBOT regions adjacent to a MOC (14/20) than in pure MBOTs (3/15) ( P =0.024). Expression of the tumor marker L1-CAM is frequent (51%) in MOC and is associated with tumor recurrence. The lack of L1-CAM may serve to characterize cases with a low risk of recurrence. Furthermore, the presence of specific molecular alterations in MBOTs is associated with adjacent carcinomas and may define potential pathways in tumor progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
The American journal of surgical pathology - 47(2023), 5 vom: 01. Mai, Seite 558-567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wiedenhoefer, Rebekka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.04.2023 Date Revised 22.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/PAS.0000000000002027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353585939 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353585939 | ||
| 003 | DE-627 | ||
| 005 | 20231226060338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/PAS.0000000000002027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353585939 | ||
| 035 | |a (NLM)36852510 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wiedenhoefer, Rebekka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors |b Impact on Tumor Recurrence and Potential Role in Tumor Progression |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2023 | ||
| 500 | |a Date Revised 22.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a Mucinous ovarian carcinoma (MOC) is a rare histotype of primary ovarian carcinoma. Frequent pathogenic molecular alterations include mutations in KRAS , TP53 , and overexpression of human epidermal growth factor receptor 2, but without having prognostic relevance. As L1-CAM (cell adhesion molecule) has previously shown prognostic relevance in other epithelial tumors of the female genital tract, we analyzed whether L1-CAM expression affected MOC prognosis. In addition, we investigated L1-CAM expression in mucinous borderline tumors (MBOTs) with and without adjacent MOC to identify its potential role in the pathogenesis of MOC. We examined a well-characterized collective of 39 MOCs by immunohistochemistry and compared their expression with clinicopathologic data. L1-CAM positivity was defined as any (even single-cell) positivity. Furthermore, we compared the L1-CAM expression in 20 MBOT regions adjacent to a MOC with that of 15 pure MBOTs. L1-CAM expression in MOC was significantly associated with recurrence, independent of tumor stage. Overall, 7/20 positive cases recurred versus 0/19 L1-CAM-negative cases ( P =0.032), showing a significant difference in time to progression. Furthermore, the presence of at least 1 defined molecular alteration (L1-CAM, aberrant p53, or human epidermal growth factor receptor 2) was found more frequently in the MBOT regions adjacent to a MOC (14/20) than in pure MBOTs (3/15) ( P =0.024). Expression of the tumor marker L1-CAM is frequent (51%) in MOC and is associated with tumor recurrence. The lack of L1-CAM may serve to characterize cases with a low risk of recurrence. Furthermore, the presence of specific molecular alterations in MBOTs is associated with adjacent carcinomas and may define potential pathways in tumor progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Neural Cell Adhesion Molecule L1 |2 NLM | |
| 700 | 1 | |a Schmoeckel, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Grube, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Sulyok, Mihály |e verfasserin |4 aut | |
| 700 | 1 | |a Pasternak, Iana |e verfasserin |4 aut | |
| 700 | 1 | |a Beschorner, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Greif, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Brucker, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Mayr, Doris |e verfasserin |4 aut | |
| 700 | 1 | |a Kommoss, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Fend, Falko |e verfasserin |4 aut | |
| 700 | 1 | |a Staebler, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Anna K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of surgical pathology |d 1987 |g 47(2023), 5 vom: 01. Mai, Seite 558-567 |w (DE-627)NLM000259993 |x 1532-0979 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:558-567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/PAS.0000000000002027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2023 |e 5 |b 01 |c 05 |h 558-567 | ||